The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM D

OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity			
CIK (Filer ID Number)	Previous	None	Entity Type
0001953926	Names		
Name of Issuer	Zenas Biorna	ırma (Cayman) Ltd	X Corporation
Zenas BioPharma, Inc.			Limited Partnership
Jurisdiction of Incorporation/Org	ranization		Limited Liability Company
DELAWARE	gariizatiori		General Partnership
Year of Incorporation/Organizati	ion		Business Trust
Over Five Years Ago	ion		Other (Specify)
=	wife Voor\ 2022		
Within Last Five Years (Spe	City feat / 2023		
Yet to Be Formed			
2. Principal Place of Business	and Contact Information		
Name of Issuer			
Zenas BioPharma, Inc.			
Street Address 1		Street Address 2	
1000 WINTER ST, SUITE 1200			
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
WALTHAM	MASSACHUSETTS	02451	857-271-2954
3. Related Persons			
Last Name	First Name		Middle Name
MOULDER, JR.	LEON		O.
Street Address 1	Street Address 2		o.
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST,	SUITE 1200	
City	State/Province/Co		ZIP/PostalCode
WALTHAM	MASSACHUSETT		02451
Relationship: X Executive Office	cer X Director Promoter		
Clarification of Response (if Nec	eessary):		
Last Name	First Name		Middle Name
FARMER	JOSEPH		Wilddio Name
Street Address 1	Street Address 2		
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST,	SUITE 1200	
City	State/Province/Co		ZIP/PostalCode
WALTHAM	MASSACHUSETT		02451
Relationship: X Executive Office	<u> </u>		
Clarification of Response (if Nec			
Last Name	First Name		Middle Name
KISELAK	TOMAS		
Street Address 1	Street Address 2		
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST,		
City	State/Province/Co		ZIP/PostalCode
WALTHAM	MASSACHUSETT	S	02451
Relationship: Executive Office	cer X Director Promoter		

Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
LU	HONGBO		
Street Address 1	Street Address 2		
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST, SUITE 1200		
City	State/Province/Country	ZIP/PostalCode	
WALTHAM	MASSACHUSETTS	02451	
Relationship: Executive Officer	_		
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
BOYLAN	JAMES	PATRICK	
Street Address 1	Street Address 2	FAIRICK	
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST, SUITE 1200		
City	State/Province/Country	ZIP/PostalCode	
WALTHAM	MASSACHUSETTS	02451	
	_	02+31	
	Director Promoter		
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
ENRIGHT	PATRICK	GERALD	
Street Address 1	Street Address 2		
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST, SUITE 1200		
City	State/Province/Country	ZIP/PostalCode	
WALTHAM	MASSACHUSETTS	02451	
Relationship: Executive Officer	Director Promoter		
Clarification of Response (if Necessa	ry):		
Loot Name	First Name	Middle Name	
Last Name	First Name	Middle Name	
ORLOFF Street Address 1	JOHN Street Address 2	JACOB	
	Street Address 2		
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST, SUITE 1200	71D/Da atal Ca da	
City WALTHAM	State/Province/Country MASSACHUSETTS	ZIP/PostalCode 02451	
	_	02431	
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
NUNN	JAKE		
Street Address 1	Street Address 2		
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST, SUITE 1200		
City	State/Province/Country	ZIP/PostalCode	
WALTHAM	MASSACHUSETTS	02451	
Relationship: Executive Officer	Director Promoter		
Clarification of Response (if Necessa	ry):		
Last Name	First Name	Middle Name	
XIAO	TIM		
Street Address 1	Street Address 2		
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST, SUITE 1200		
City	State/Province/Country	ZIP/PostalCode	
WALTHAM	MASSACHUSETTS	02451	
Relationship: Executive Officer			
Clarification of Response (if Necessa			
Ciamication of Response (if Necessa			
Last Name	First Name	Middle Name	

ALLEN	PATRICIA	
Street Address 1	Street Address 2	
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST, SUITE 1200	
City	State/Province/Country	ZIP/PostalCode
WALTHAM	MASSACHUSETTS	02451
Relationship: Executive Officer X Dir	ector Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
FOX	JENNIFER	
Street Address 1	Street Address 2	
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST, SUITE 1200	
City	State/Province/Country	ZIP/PostalCode
WALTHAM	MASSACHUSETTS	02451
Relationship: X Executive Officer Dir	ector Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
FISCHER	TANYA	Z.
Street Address 1	Street Address 2	
C/O ZENAS BIOPHARMA, INC.	1000 WINTER ST, SUITE 1200	
City	State/Province/Country	ZIP/PostalCode
WALTHAM	MASSACHUSETTS	02451
Relationship: X Executive Officer Dir	ector Promoter	
Clarification of Response (if Necessary):		
4. Industry Group		
		_
Agriculture	Health Care	Retailing
Banking & Financial Services	X Biotechnology	Restaurants
Commercial Banking	Health Insurance	Technology
Insurance	Hospitals & Physicians	
Investing		Computers
Investment Banking	Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under	Real Estate	Airlines & Airports
the Investment Company Act of 1940?	Commercial	
∏Yes		Lodging & Conventions
	Construction	Tourism & Travel Services
Other Banking & Financial Service	REITS & Finance	Other Travel
Business Services	Residential	Other
Energy	Other Real Estate	Other
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net Asset Va	alue Range
No Revenues	No Aggregate Net A	-
\$1 - \$1,000,000	\$1 - \$5,000,000	
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,00	0.000
 		

	 \$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000		
	\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000		
	Over \$100,000,000	H	Over \$100,000,000		
X	Decline to Disclose Decline to Disclose				
	Not Applicable		Not Applicable		
6	Federal Exemption(s) and Exclusion(s) Claime	d (4	coloct all that anniv)		
<u> </u>	ederal Exemption(s) and Exclusion(s) Claimer	<u>u (</u>	refect all triat appryy		
		[Investment Company Act Section 3(c)		
Г	Rule 504(b)(1) (not (i), (ii) or (iii))	[Section 3(c)(1) Section 3(c)(9)		
Ť	Rule 504 (b)(1)(i)	ſ	Section 3(c)(2) Section 3(c)(10)		
Ī	Rule 504 (b)(1)(ii)	[Section 3(c)(3) Section 3(c)(11)		
	Rule 504 (b)(1)(iii)	۱ آ			
2	Rule 506(b)] 1			
Ļ	Rule 506(c)	l	Section 3(c)(5) Section 3(c)(13)		
L	Securities Act Section 4(a)(5)	Į	Section 3(c)(6) Section 3(c)(14)		
		[Section 3(c)(7)		
_					
7.	Type of Filing				
X	New Notice Date of First Sale 2024-05-03	irst	Sale Yet to Occur		
	Amendment				
8.	Duration of Offering				
_			- var 2 Var VA		
DC	es the Issuer intend this offering to last more than	ı or	e year? Yes X No		
9.	Type(s) of Securities Offered (select all that ap	ply			
X	Equity		Pooled Investment Fund Interests		
F	Debt		Tenant-in-Common Securities		
	Option, Warrant or Other Right to Acquire Anothe	er S	Security Mineral Property Securities		
X	Security to be Acquired Upon Exercise of Option	, W	arrant or Other Other (describe)		
<u> </u>	Right to Acquire Security				
10. Business Combination Transaction					
	this offering being made in connection with a busingerger, acquisition or exchange offer?	nes	s combination transaction, such as a Yes X No		
Cla	urification of Response (if Necessary):				
	Minimum Investment				
Mi	nimum investment accepted from any outside inve	esto	or \$0 USD		
12.	Sales Compensation	_			
Re	ecipient		Recipient CRD Number X None		
(Δ	ssociated) Broker or Dealer X None		(Associated) Broker or Dealer CRD Number X None		
	reet Address 1		Street Address 2		
Ci	y		State/Province/Country	ZIP/Postal Code	
	ate(s) of Solicitation (select all that apply) neck "All States" or check individual States	Sta	tes Foreign/non-US		
13.	Offering and Sales Amounts				
Te	tal Offering Amount \$200,145,722 USD	 ۱	dofinito		
		Jın	definite		
	tal Amount Sold \$200,145,732 USD	٦,,	dofinito		
10	tal Remaining to be Sold \$0 USD or	∫ın	definite		
Cla	rification of Response (if Necessary):				

14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited
investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$0 USD Estimate
Finders' Fees \$0 USD Estimate
Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$0 USD Estimate
Clarification of Response (if Necessary):
Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice

) file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- · Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Zenas BioPharma, Inc.	JOSEPH FARMER	JOSEPH FARMER	PRESIDENT AND CHIEF OPERATING OFFICER	2024-05-14

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.